Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...

Fractyl Health offers a buy-the-dip opportunity after an overreaction to underwhelming six-month pilot data for its Revita ...

Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announce ...

They covered his eyes so he'd be less anxious — wait to see how they finally got him out ️ Mexico's president says it was 'sovereign decision' to send cartel members to US Another sphere is planned ...

Cancel anytime. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service ...

Corneal shape does not appear to be affected significantly by either high- or low-concentration atropine in children.

Smart developers constrain AI to write code within their company’s preexisting ecosystem and security guidelines.

Smart developers constrain AI to write code within their company’s preexisting ecosystem and security guidelines.

An email rarely elicits genuine, audible gasps, but I opened one in late 2009 that did just that. I was a fifth-year federal prosecutor at the United States Attorney’s Office for the Southern District ...

Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial) Personalized dosing of ...